Literature DB >> 17145593

Predicting survival and leukemic evolution in patients with myelodysplastic syndrome.

Luca Malcovati, Matteo Giovanni Della Porta, Mario Cazzola.   

Abstract

Entities:  

Mesh：

Year:  2006        PMID： 17145593

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  34 in total

Review 1.  Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Authors:  Heather A Leitch
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Authors:  Matteo G Della Porta; Cristina Picone; Cristiana Pascutto; Luca Malcovati; Hideto Tamura; Hiroshi Handa; Magdalena Czader; Sylvie Freeman; Paresh Vyas; Anna Porwit; Leonie Saft; Theresia M Westers; Canan Alhan; Claudia Cali; Arjan A van de Loosdrecht; Kiyoyuki Ogata
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

3.  A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.

Authors:  Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; Farhad Ravandi; Gautam Borthakur; Zeev Estrov; Varsha Gandhi; Anna L Byrd; Monica Kwari; Jorge Cortes; Hagop M Kantarjian
Journal:  Cancer       Date:  2011-07-12       Impact factor: 6.860

4.  Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Authors:  Mario Cazzola
Journal:  Haematologica       Date:  2011-03       Impact factor: 9.941

Review 5.  Iron overload in myelodysplastic syndromes (MDS).

Authors:  Norbert Gattermann
Journal:  Int J Hematol       Date:  2017-11-25       Impact factor: 2.490

6.  Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study.

Authors:  Emilio Paolo Alessandrino; Matteo Giovanni Della Porta; Andrea Bacigalupo; Luca Malcovati; Emanuele Angelucci; Maria Teresa Van Lint; Michele Falda; Francesco Onida; Massimo Bernardi; Stefano Guidi; Barbarella Lucarelli; Alessandro Rambaldi; Raffaella Cerretti; Paola Marenco; Pietro Pioltelli; Cristiana Pascutto; Rosi Oneto; Laura Pirolini; Renato Fanin; Alberto Bosi
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

Review 7.  [Individualized management and therapy of myelodysplastic syndromes].

Authors:  Reinhard Stauder; Friedrich Wimazal; Thomas Nösslinger; Otto Krieger; Wolfgang R Sperr; Heinz Sill; Michael Pfeilstöcker; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2008       Impact factor: 1.704

8.  Iron chelation therapy in myelodysplastic syndromes.

Authors:  Emanuela Messa; Daniela Cilloni; Giuseppe Saglio
Journal:  Adv Hematol       Date:  2010-06-20

9.  Prognostic factors in myelodysplastic syndromes.

Authors:  Irina Triantafyllidis; Anca Ciobanu; Oana Stanca; Anca Roxana Lupu
Journal:  Maedica (Buchar)       Date:  2012-12

10.  A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes.

Authors:  Jun Ho Jang; Hironori Harada; Hirohiko Shibayama; Ryutaro Shimazaki; Hyeoung-Joon Kim; Kenichi Sawada; Kinuko Mitani
Journal:  Int J Hematol       Date:  2015-09-01       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.